Acutus Medical, Inc.
AFIB · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.01 | 0.02 |
| FCF Yield | -1,940.57% | -1,078.20% | -271.87% | -112.22% |
| EV / EBITDA | 10.40 | -4.73 | 1.31 | -1.13 |
| Quality | ||||
| ROIC | -0.24% | -38.40% | -20.16% | -76.39% |
| Gross Margin | 5.03% | -43.79% | -63.02% | -90.73% |
| Cash Conversion Ratio | 6.98 | 1.59 | 2.15 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 88.05% | -25.41% | -28.99% | 82.59% |
| Free Cash Flow Growth | 49.84% | 28.85% | 18.82% | -13.76% |
| Safety | ||||
| Net Debt / EBITDA | 9.67 | -3.62 | 0.38 | -0.20 |
| Interest Coverage | -0.01 | -2.54 | -4.46 | -20.41 |
| Efficiency | ||||
| Inventory Turnover | 10.69 | 2.41 | 2.39 | 2.01 |
| Cash Conversion Cycle | 152.45 | 632.18 | 2,848.35 | 175.36 |